Pfizer, BioNTech To Supply US Government 600M Doses Of Coronavirus Vaccine

Friday, 24 Jul, 2020

Two days ago, they announced a positive update on its vaccine study, which included the first T cell response data.

With Oxford reaching a third late-stage clinical trial, it paves way for the vaccine being developed by the University to be reviewed by regulators before it could be approved for wide use.

Almost 40 lakh Americans have been infected by the new coronavirus and at least 1.43 lakh have died from COVID-19, according to Johns Hopkins. "A vaccine is meaningless if people are unable to afford it". T-cells are a type of white blood cell that helps the immune system to identify the infected body's cells and destroy them.

"An interesting thing about this vaccine approach is that the mRNA is enclosed in a lipid nanoparticle, so you can imagine the complexity of that".

"Americans will receive the vaccine for free consistent with US government's commitment for free access for COVID-19 vaccines", the companies said.

On Monday, the companies agreed to supply the United Kingdom with 30 million doses of the vaccine candidate, but did not disclose a price. If needed, the government will extend its financial coffers further to new companies as well.

"The vaccine candidate shows no unexpected very bad adverse effects", mr Rath told PTI, adding that the formal addition of paracetamol showing some relief from adverse effects without modifying immune responses is useful information too.

President Trump told Fox News medical contributor Marc Siegel on Wednesday that he's in an impossible situation regarding whether he should be the first to take a coronavirus vaccine.

The vaccine uses a weakened version of a common-cold virus that encodes instructions for making proteins from the SARS-CoV-2 virus, which causes the coronavirus disease, to build immunity.

"We will not sell it at cost", said Dr. Stephen Hoge, the president of Moderna. No serious adverse events were reported.

These results showed that the injection triggered the production of antibodies and T-cells that can fight coronavirus in the body of the study volunteers.

"Generating immune response and providing immunological protection might not always run parallel", Ms Ray said. "Ethics is of the utmost importance in any scientific study". Pointing to the way forward, she said there should be elaborate trials in geographical locations where severities and mortality of COVID-19 are now high. "The study needs to be run longer", Ms Ray said. Data is expected by August or September, with first doses expected between September and October.

Digital special projects editor Lauren Young asked participants which vaccine candidates show the most promise, and what to expect in terms of prevention, safety and vaccine roll out.

However, none of the on-going global vaccine development efforts matches that of Oxford University, which reportedly has received a lot of funding from different players.